Review Article| Volume 39, ISSUE 2, P277-285, April 2023

Cytokine Release Syndrome in the Pediatric Population and Implications for Intensive Care Management

Published:November 17, 2022DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Critical Care Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rheingold S.R.
        • Ji L.
        • Xu X.
        • et al.
        Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children’s Oncology Group (COG) study.
        Am Soc Clin Oncol. 2019; 37 (10008–10008)
        • Shalabi H.
        • Gust J.
        • Taraseviciute A.
        • et al.
        Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.
        Nat Rev Clin Oncol. 2021; 18: 363-378
        • Grupp S.A.
        • Kalos M.
        • Barrett D.
        • et al.
        Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
        N Engl J Med. 2013; 368: 1509-1518
        • Mackall C.L.
        • Merchant M.S.
        • Fry T.J.
        Immune-based therapies for childhood cancer.
        Nat Rev Clin Oncol. 2014; 11: 693-703
        • Shah N.N.
        • Lee D.W.
        • Yates B.
        • et al.
        Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-all.
        J Clin Oncol. 2021; 39: 1650-1659
        • Ramos C.A.
        • Heslop H.E.
        • Brenner M.K.
        CAR-T cell therapy for lymphoma.
        Annu Rev Med. 2016; 67: 165-183
        • Marofi F.
        • Rahman H.S.
        • Achmad M.H.
        • et al.
        A deep insight into CAR-T cell therapy in non-hodgkin lymphoma: application, opportunities, and future directions.
        Front Immunol. 2021; 12: 681984
        • Davila M.L.
        • Riviere I.
        • Wang X.
        • et al.
        Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
        Sci Transl Med. 2014; 6: 224ra25
        • CAR T.
        • National Cancer Institute
        Cells: engineering patients’ immune cells to treat their cancers.
        (Available at:) (Accessed June 18th, 2022)
        • June C.H.
        • Sadelain M.
        Chimeric antigen receptor therapy.
        N Engl J Med. 2018; 379: 64-73
        • Fajgenbaum D.C.
        • June C.H.
        Cytokine storm.
        N Engl J Med. 2020; 383: 2255-2273
        • Baumeister S.H.C.
        • Mohan G.S.
        • Elhaddad A.
        • et al.
        Cytokine release syndrome and associated acute toxicities in pediatric patients undergoing immune effector cell therapy or hematopoietic cell transplantation.
        Front Oncol. 2022; 12: 841117
      1. DeAngelo D.J., Ghobadi A., Park J.H., et al. Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study). Presented at: 32nd Annual SITC Meeting, National Harbor, MD, November 8-12. Poster P217.

        • Maude S.L.
        • Laetsch T.W.
        • Buechner J.
        • et al.
        Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.
        N Engl J Med. 2018; 378: 439-448
        • Lee D.W.
        • Santomasso B.D.
        • Locke F.L.
        • et al.
        ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.
        Biol Blood Marrow Transpl. 2019; 25: 625-638
        • Klinger M.
        • Brandl C.
        • Zugmaier G.
        • et al.
        Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
        Blood. 2012; 119: 6226-6233
        • Imus P.H.
        • Blackford A.L.
        • Bettinotti M.
        • et al.
        Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation.
        Biol Blood Marrow Transpl. 2019; 25: 2431-2437
        • Lee D.W.
        • Gardner R.
        • Porter D.L.
        • et al.
        Current concepts in the diagnosis and management of cytokine release syndrome.
        Blood. 2014; 124: 188-195
        • Maude S.L.
        • Barrett D.
        • Teachey D.T.
        • et al.
        Managing cytokine release syndrome associated with novel T cell-engaging therapies.
        Cancer J. 2014; 20: 119-122
        • Teachey D.T.
        • Lacey S.F.
        • Shaw P.A.
        • et al.
        Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.
        Cancer Discov. 2016; 6: 664-679
        • Sheth V.S.
        • Gauthier J.
        Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL.
        Bone Marrow Transpl. 2021; 56: 552-566
        • Kadauke S.
        • Myers R.M.
        • Li Y.
        • et al.
        Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial.
        J Clin Oncol. 2021; 39: 920-930
        • Mahadeo K.M.
        • Khazal S.J.
        • Abdel-Azim H.
        • et al.
        Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.
        Nat Rev Clin Oncol. 2019; 16: 45-63
        • Shalabi H.
        • Sachdev V.
        • Kulshreshtha A.
        • et al.
        Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
        J Immunother Cancer. 2020; 8
        • Fitzgerald J.C.
        • Weiss S.L.
        • Maude S.L.
        • et al.
        Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia.
        Crit Care Med. 2017; 45: e124-e131
        • Gutierrez C.
        • McEvoy C.
        • Munshi L.
        • et al.
        Critical care management of toxicities associated with targeted agents and immunotherapies for cancer.
        Crit Care Med. 2020; 48: 10-21
      2. Pediatric acute lung injury consensus conference G. Pediatric acute respiratory distress syndrome: consensus recommendations from the pediatric acute lung injury consensus conference.
        Pediatr Crit Care Med. 2015; 16: 428-439